| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $2,351,000 | 2 | 6 |
Sells | $3,842,625 | 29 | 94 |
| WILSON TROY EDWARD | President and CEO | 2 | $2.35M | 0 | $0 | $2.35M |
| Hasnain Faheem | director | 0 | $0 | 1 | $109,764 | $-109,764 |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting | 0 | $0 | 3 | $159,519 | $-159,519 |
| FORD KATHLEEN | Chief Operating Officer | 0 | $0 | 5 | $224,896 | $-224,896 |
| Burrows Francis | Chief Scientific Officer | 0 | $0 | 3 | $467,538 | $-467,538 |
| Powl Brian T. | Chief Commercial Officer | 0 | $0 | 7 | $663,417 | $-663,417 |
| Bair Teresa Brophy | Chief Legal Officer | 0 | $0 | 5 | $700,688 | $-700,688 |
| Leoni Mollie | Chief Medical Officer | 0 | $0 | 5 | $1.52M | $-1.52M |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional …
Over the last 12 months, insiders at Kura Oncology, Inc. have bought $2.35M and sold $3.84M worth of Kura Oncology, Inc. stock.
On average, over the past 5 years, insiders at Kura Oncology, Inc. have bought $1.21M and sold $1.81M worth of stock each year.
Highest buying activity among insiders over the last 12 months: WILSON TROY EDWARD (President and CEO) — $2.35M.
The last purchase of 100,000 shares for transaction amount of $1.24M was made by WILSON TROY EDWARD (President and CEO) on 2026‑08‑24.
| 2026-09-29 | Sale | FORD KATHLEEN | Chief Operating Officer | 3,668 0.0041% | $10.75 | $39,437 | -7.64% | |
| 2026-09-29 | Sale | Leoni Mollie | Chief Medical Officer | 28,802 0.0323% | $10.75 | $309,567 | -7.64% | |
| 2026-09-29 | Sale | Powl Brian T. | Chief Commercial Officer | 15,430 0.0173% | $10.75 | $165,852 | -7.64% | |
| 2026-09-28 | Sale | Bair Teresa Brophy | Chief Legal Officer | 8,442 0.0094% | $10.50 | $88,618 | -4.62% | |
| 2026-09-28 | Sale | Leoni Mollie | Chief Medical Officer | 12,448 0.0139% | $10.50 | $130,670 | -4.62% | |
| 2026-09-28 | Sale | Powl Brian T. | Chief Commercial Officer | 17,020 0.019% | $10.53 | $179,183 | -4.62% | |
| 2026-09-28 | Sale | FORD KATHLEEN | Chief Operating Officer | 6,906 0.0077% | $10.50 | $72,494 | -4.62% | |
| 2026-09-28 | Sale | DOYLE THOMAS JAMES | SVP, Finance & Accounting | 4,607 0.0051% | $10.50 | $48,361 | -4.62% | |
| 2026-09-24 | Sale | Burrows Francis | Chief Scientific Officer | 20,726 0.0233% | $10.83 | $224,514 | -4.90% | |
| 2026-08-24 | WILSON TROY EDWARD | President and CEO | 100,000 0.1125% | $12.39 | $1.24M | -13.59% | ||
| 2026-08-21 | Sale | Powl Brian T. | Chief Commercial Officer | 4,345 0.0049% | $11.89 | $51,663 | -9.84% | |
| 2026-08-19 | Sale | Bair Teresa Brophy | Chief Legal Officer | 31,487 0.0358% | $12.63 | $397,681 | -14.13% | |
| 2026-08-17 | WILSON TROY EDWARD | President and CEO | 100,000 0.1109% | $11.12 | $1.11M | -4.21% | ||
| 2026-06-18 | Sale | Leoni Mollie | Chief Medical Officer | 84,929 0.0946% | $9.82 | $834,283 | +7.96% | |
| 2026-05-21 | Sale | Powl Brian T. | Chief Commercial Officer | 10,000 0.0111% | $11.00 | $110,000 | -4.72% | |
| 2026-05-19 | Sale | Powl Brian T. | Chief Commercial Officer | 339 0.0004% | $9.21 | $3,122 | +18.36% | |
| 2026-05-19 | Sale | FORD KATHLEEN | Chief Operating Officer | 2,257 0.0026% | $9.08 | $20,483 | +18.36% | |
| 2026-05-18 | Sale | Bair Teresa Brophy | Chief Legal Officer | 2,256 0.0026% | $9.38 | $21,160 | +15.22% | |
| 2026-01-27 | Sale | Leoni Mollie | Chief Medical Officer | 8,180 0.0094% | $8.46 | $69,209 | +12.99% | |
| 2026-01-27 | Sale | Bair Teresa Brophy | Chief Legal Officer | 11,208 0.0129% | $8.46 | $94,828 | +12.99% |
| WILSON TROY EDWARD | President and CEO | 479194 0.5387% | $4.73M | 5 | 14 | +36.57% |
| EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 4408097 4.9551% | $43.55M | 8 | 1 | +14.44% |
| Malley Thomas | director | 139557 0.1569% | $1.38M | 2 | 0 | <0.0001% |
$100,473,344 | 83 | 9.53% | $826.91M | |
$15,410,062 | 81 | 39.69% | $975.93M | |
$5,911,307 | 70 | -1.38% | $884.8M | |
$1,108,102,085 | 66 | 36.91% | $755.04M | |
$11,663,618 | 57 | 32.20% | $934.29M |
| Increased Positions | 136 | +71.96% | 12M | +13.97% |
| Decreased Positions | 81 | -42.86% | 10M | -11.86% |
| New Positions | 44 | New | 2M | New |
| Sold Out Positions | 26 | Sold Out | 3M | Sold Out |
| Total Postitions | 244 | +29.1% | 86M | +2.11% |
| Blackrock, Inc. | $98,339.00 | 10.94% | 9.52M | +44,802 | +0.47% | 2025-09-30 |
| Bvf Inc/Il | $89,058.00 | 9.9% | 8.62M | +863,033 | +11.13% | 2025-09-30 |
| Suvretta Capital Management, Llc | $83,879.00 | 9.33% | 8.12M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $56,517.00 | 6.29% | 5.47M | +120,197 | +2.25% | 2025-09-30 |
| Armistice Capital, Llc | $48,285.00 | 5.37% | 4.67M | -2M | -24.64% | 2025-09-30 |
| State Street Corp | $34,551.00 | 3.84% | 3.34M | +306,273 | +10.09% | 2025-09-30 |
| Prosight Management, Lp | $28,509.00 | 3.17% | 2.76M | -422,668 | -13.29% | 2025-09-30 |
| Goldman Sachs Group Inc | $27,023.00 | 3.01% | 2.61M | +2M | +180.05% | 2025-09-30 |
| Aqr Capital Management Llc | $23,173.00 | 2.58% | 2.24M | +1M | +138.11% | 2025-09-30 |
| Jacobs Levy Equity Management, Inc | $22,991.00 | 2.56% | 2.22M | +1M | +101.62% | 2025-09-30 |